AlphaThera has announced its relocation to a significantly larger laboratory and office facility at 3675 Market Street, in the heart of University City. The move provides the biotech company with twice the space of its prior location and marks another milestone in its steady growth trajectory.
The expanded facility will integrate both laboratory and office space, enabling AlphaThera to scale research and development around its flagship oYo-Link® Antibody Labeling Technology. Since its founding, the company has built a reputation for advancing antibody conjugation, with the oYo-Link® Oligo technology setting new benchmarks in spatial biology. The company’s conjugation services have also gained traction among biotech companies and academic researchers in the U.S. and internationally for their quality and cost-effectiveness.
AlphaThera’s recent partnership with Columbia Biosciences highlights its continued momentum. Together, they are preparing to launch two new oYo-Link® SureLight® fluorescent proteins in the coming months, expanding the platform’s reach and applications in antibody labeling.
“The additional space will allow us to build on the success of oYo-Link with more facilities to expand our R&D capacity, while continuing to meet the needs of our growing customer base,” said Dr. Andrew Tsourkas, Co-Founder of AlphaThera. “The move not only expands our capacity but also places the team in a vibrant location with improved facilities and surroundings.”
This relocation follows AlphaThera’s earlier 2023 move into the Pennovation Works Lab Building at the University of Pennsylvania, a step that positioned the company for growth at the time. By moving now into 3675 Market Street — a prominent anchor in the uCity Square knowledge community — AlphaThera places itself alongside a growing cluster of biotech firms benefiting from proximity to world-class research institutions, talent pipelines, and shared infrastructure.
Philadelphia’s biotech real estate market has seen a surge of activity, underscoring the ecosystem AlphaThera is part of. Spark Therapeutics is investing $575 million in its Gene Therapy Innovation Center on Drexel University’s campus, slated to open in 2026. Meanwhile, Legend Biotech has announced plans for a new 31,000-square-foot R&D facility in the city, and incubators like BioLabs are expanding to provide more shared lab space for emerging companies. These moves, alongside AlphaThera’s, reflect the confidence in Philadelphia as a hub for next-generation therapeutics and research.
For AlphaThera, the new facility represents both a scaling opportunity and a strategic position in one of the nation’s most dynamic biotech corridors. With expanded R&D capacity and the launch of new products on the horizon, the company is positioning itself to continue shaping the antibody labeling space while contributing to the momentum of Philadelphia’s life sciences ecosystem.
